

Available online on 15.06.2026 at <http://ajprd.com>

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-25, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Research Article

Development and Optimization of Liquisolid Compact Tablet of Ebastine

Jaymina Panthaki^{1*}, Dr. Shruti Barot², Amar M. Raval¹, Dr. Khushboo Vaghela³, Dr. Disha Suthar¹¹Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat Technological University, Ahmedabad, Gujarat, India.² Department of Pharmaceutics, Parul Institute of Pharmacy, Parul University, Gujarat, India.⁴Department of Pharmacognosy, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat Technological University, Ahmedabad, Gujarat, India.

ABSTRACT

Ebastine is a second-generation non-sedating antihistaminic drug indicated for the prevention and treatment of allergic rhinitis and chronic idiopathic urticaria. It is classified under Biopharmaceutical Classification System Class II and exhibits poor aqueous solubility, resulting in dissolution-limited oral absorption. The present work was undertaken to develop and optimize liquisolid compact tablets of Ebastine in order to improve dissolution behavior and pharmaceutical performance.

Solubility of Ebastine was evaluated in various non-volatile solvents. Based on maximum drug solubility, Cremophor RH 40 was selected as non-volatile liquid vehicle. Neusilin US2 and Aerosil 200 were selected as carrier and coating materials respectively. Drug-excipient compatibility studies were performed using Fourier Transform Infrared Spectroscopy and Differential Scanning Calorimetry. The formulation was optimized using Design Expert® version 10 software by response surface methodology employing 3² full factorial design. Drug concentration in liquid medication (Cd) and carrier-coating ratio (R) were selected as independent variables, while angle of repose and cumulative percentage drug release at 20 minutes were selected as dependent responses.

The optimized formulation was obtained with Cd value of 15.0 and carrier-coating ratio of 26.7. Validation batches confirmed close agreement between predicted and observed values. Crospovidone was selected as suitable superdisintegrant and optimized at 7%. The optimized formulation showed acceptable flow properties and post-compression characteristics. Comparative dissolution study demonstrated faster release than marketed conventional tablet. FTIR studies confirmed compatibility between drug and excipients. DSC and PXRD analysis indicated reduced crystallinity and improved dispersion of drug in final formulation. Accelerated stability study at 40 ±2°C and 75 ±5% RH for one month showed no remarkable change in tablet characteristics.

The study confirmed that liquisolid compact technology is a promising and effective approach for enhancing dissolution of poorly water-soluble Ebastine.

Keywords: Ebastine, Liquisolid compact, dissolution enhancement, Cremophor RH 40, factorial design,

ARTICLE INFO: Received 17 Dec. 2025; Review Complete 13 March., 2026; Accepted 15 May. 2026; Available online 15 June 2026



Cite this article as:

Panthaki J, Dr. Barot S, Raval AM, Vaghela K, Suthar D, Development and Optimization of Liquisolid Compact Tablet of Ebastine, Asian Journal of Pharmaceutical Research and Development. 2026; 14(3):65-77, DOI: <http://dx.doi.org/10.22270/ajprd.v14i3.1759>

*Address for Correspondence:

Roma Rupesh Kasar, Department of Quality Assurance, Matoshri Institute of Pharmacy, Dhanore, Yeola, Maharashtra, India.

INTRODUCTION

Oral drug delivery remains the most preferred and widely accepted route of administration due to patient convenience, cost effectiveness, ease of manufacturing, and improved compliance. Tablets and capsules represent the most commonly prescribed pharmaceutical dosage forms because they are stable, portable, and allow accurate dose administration.

Despite these advantages, one of the most significant challenges associated with oral dosage forms is poor aqueous solubility of drug molecules. Drug solubility directly influences dissolution behavior, absorption, and ultimately bioavailability. A drug intended for oral administration must first dissolve in gastrointestinal fluids before permeating through biological membranes. When solubility is poor, dissolution becomes slow and incomplete, leading to delayed onset of action and lower systemic availability.

Biopharmaceutical Classification System

The Biopharmaceutical Classification System classifies drugs on the basis of aqueous solubility and intestinal permeability into four categories.

Class I: high solubility and high permeability

Class II: low solubility and high permeability

Class III: high solubility and low permeability

Class IV: low solubility and low permeability

For BCS Class II drugs, dissolution is the rate-limiting step for absorption. Therefore, improvement of dissolution significantly influences therapeutic performance.

Ebastine belongs to BCS Class II. It demonstrates good permeability but poor aqueous solubility, making dissolution enhancement a critical formulation objective.

Approaches used for dissolution enhancement

Various formulation techniques are reported to improve dissolution of poorly soluble drugs.

Common approaches include:

- Micronization
- Nanocrystal Formation
- Solid Dispersion
- Ph Adjustment
- Co-Solvency
- Cyclodextrin Complexation
- Self-Emulsifying Systems
- Salt Formation
- Hydrotropy
- Lquisolid Systems

Although several techniques are effective, many involve expensive equipment, complicated processing, or scale-up limitations. Lquisolid compact technology provides a comparatively simple and practical alternative.

Lquisolid compact technology

Lquisolid compact technology involves dissolving or suspending the drug in a non-volatile liquid vehicle and converting this liquid medication into dry, non-adherent, free-flowing and compressible powder by blending with selected carrier and coating materials.

The technique improves dissolution through:

- enhanced wetting
- increased molecular dispersion
- larger effective surface area
- improved penetration of dissolution medium
- possible reduction in crystallinity

The technology is attractive because it can be processed using conventional tablet compression and does not require sophisticated instrumentation.

Drug profile of Ebastine

Ebastine is a second-generation H1 antihistamine used in management of allergic disorders.

Therapeutic indications include, allergic rhinitis & chronic idiopathic urticaria. It offers, prolonged duration of action,

effective symptom relief, minimal sedation, However, its poor aqueous solubility limits dissolution and may affect oral bioavailability. Improving dissolution of Ebastine is therefore pharmaceutically relevant.

Allergic rhinitis and therapeutic importance

Allergic rhinitis is an inflammatory disorder of nasal mucosa mediated by immunoglobulin E. It develops after exposure to allergens and produces symptoms such as sneezing, nasal itching, rhinorrhea and congestion. The prevalence of allergic rhinitis continues to increase globally and significantly affects quality of life. Antihistamines remain first-line therapy because histamine released from mast cells is a major mediator of symptoms. Ebastine is widely prescribed because of effectiveness and favorable safety profile. Improved dissolution may contribute to faster therapeutic availability.

Rationale of present study

Ebastine demonstrates low aqueous solubility and belongs to BCS Class II. Since dissolution is the limiting factor for absorption, formulation improvement is required.

Liquisolid compact technology was selected because:

- It Enhances Wetting
- Improves Dissolution
- Supports Direct Compression
- Is Economical
- Is Reproducible
- Offers Practical Scale-Up Potential

Cremophor RH 40 was selected as liquid vehicle after solubility study. Neusilin US2 and Aerosil 200 were selected as carrier and coating system. Optimization was carried out by factorial design to obtain best formulation characteristics.

MATERIALS AND METHODS

Materials

Ebastine was obtained as a gift sample from Triveni Pharmaceutical (Vapi) Pvt. Ltd., India. Cremophor RH 40, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600 and propylene glycol were procured from Astron Chemicals (India) Pvt. Ltd. Tween 20, Tween 80 and glycerine were obtained from Loba Chemie Pvt. Ltd., Mumbai. Neusilin US2 was supplied by Gangawal Chemical Ltd., Mumbai and Aerosil 200 was obtained from Astron Chemicals (India) Pvt. Ltd. Sodium starch glycolate, croscovidone and croscarmellose sodium were used as superdisintegrants. Magnesium stearate was used as lubricant. All chemicals and reagents used during the study were of analytical grade.

Instruments

Analytical weighing balance, dissolution test apparatus, UV-visible spectrophotometer, Fourier Transform Infrared spectrophotometer, Differential Scanning Calorimeter, Powder X-ray diffractometer, rotary tablet compression machine, hardness tester, Roche friabilator, disintegration test apparatus and stability chamber were used throughout the investigation.

UV-visible analysis was performed using Shimadzu UV spectrophotometer. FTIR studies were performed using Shimadzu FTIR spectrometer. Differential scanning

calorimetry was performed using Shimadzu DSC instrument. Powder X-ray diffraction analysis was carried out using XRD system.

Preformulation studies

Preformulation study of Ebastine was carried out before formulation development to determine physical and pharmaceutical characteristics.

The study included:

- Organoleptic Evaluation
- Melting Point
- Angle Of Repose
- Bulk Density
- Tapped Density
- Carr's Index
- Hausner Ratio
- λ_{max} Determination
- FTIR
- DSC
- PXRD

These parameters helped identify the physicochemical properties of the drug and suitability for liquid formulation.

Organoleptic evaluation

Ebastine was visually examined for colour and physical appearance. The sample was found to be a white crystalline powder with uniform appearance.

Melting point determination

Melting point of Ebastine was determined using capillary tube method. Drug sample was filled into capillary tube and heated gradually. The temperature at which melting occurred was recorded. Observed melting point was found within official range.

Flow property studies

Angle of repose

Angle of repose was determined using funnel method. Powder was allowed to flow through a funnel placed at fixed height above flat surface. The angle formed by powder pile was measured.

Formula: $\tan \theta = h / r$

Where: θ = angle of repose, h = height, r = radius

Bulk density

Accurately weighed powder was transferred into measuring cylinder. Volume occupied before tapping was recorded. Formula: **Bulk density = Weight / Bulk volume**

Tapped density

Cylinder was tapped until constant volume obtained. Formula: **Tapped density = Weight / Tapped volume**

Carr's index

Formula: **Carr's Index = (Tapped density - Bulk density) / Tapped density $\times 100$**

Hausner ratio

Formula: **Hausner ratio = Tapped density / Bulk density**

UV spectrophotometric analysis

Determination of λ_{max} in methanol

Ebastine stock solution was prepared in methanol. Appropriate dilution was scanned using UV spectrophotometer. Maximum absorbance observed at **252 nm**.

Determination of λ_{max} in dissolution medium

Stock solution prepared in **0.1 M HCl containing 0.5% SLS**, Maximum absorbance recorded at **256 nm**

Calibration curve

Calibration in methanol

From the stock solution of Ebastine (1000 $\mu\text{g/ml}$), a secondary stock solution of **100 $\mu\text{g/ml}$** was prepared by transferring **10 ml** of stock solution into a **100 ml volumetric flask** and making up the volume with methanol. From this secondary stock solution, aliquots of **0.6, 0.8, 1.0, 1.2, 1.4, 1.6 and 1.8 ml** were accurately transferred into separate **10 ml volumetric flasks** and diluted up to the mark with methanol to obtain concentrations of **6, 8, 10, 12, 14, 16 and 18 $\mu\text{g/ml}$** , respectively. The absorbance of each solution was measured at **252 nm** using methanol as blank, and the calibration curve was constructed by plotting concentration versus absorbance.

Calibration in 0.1 M HCl + 0.5% SLS

100 mg of Ebastine was dissolved and then volume was made-up to 100 ml with 0.1 M HCl with containing 0.5% w/v of SLS to obtain a standard stock solution having concentration of 1000 $\mu\text{g/ml}$ of Ebastine.

FTIR spectroscopy

FTIR analysis of Ebastine was carried out by KBr pellet technique. Drug and potassium bromide were triturated and compressed. Samples scanned between: **4000-450 cm^{-1}** , Characteristic peaks were recorded.

Differential scanning calorimetry

DSC analysis was carried out to determine thermal behavior. Drug sample was placed in aluminium pan.

Temperature range: **30-250°C** Heating rate: **10°C/min**

Powder X-ray diffraction

PXRD study was performed to evaluate crystalline nature. Scanning range: **5-40° (2 θ)**, Sharp peaks confirmed crystallinity.

Solubility study

Excess Ebastine was added to selected solvents. Samples shaken for **48 hours at 25°C**, Centrifuged. Filtered.

Analyzed spectrophotometrically.

Selection of carrier and coating material

Flowable liquid-retention potential was considered. Neusilin US2 selected as carrier. Aerosil 200 selected as coating material.

Drug-excipient compatibility

Physical mixtures prepared. Analyzed by FTIR. Drug and excipients showed compatibility.

Preparation of liquisolid compact

Drug dissolved in selected liquid vehicle. Carrier material added gradually. Coating material blended. Dry free-flowing powder obtained.

Preliminary trial batches

Preliminary batches prepared to optimize:

- Carrier-Coating Ratio
- Drug Concentration

Evaluated for flow and dissolution.

Experimental design

Optimization was performed using **3² full factorial design**

Independent variables:

X₁ = Drug concentration in liquid medication

X₂ = Carrier-coating ratio

Responses:

Y₁ = Angle of repose

Y₂ = Cumulative % release at 20 min

Polynomial equation: $Y = b_0 + b_1X_1 + b_2X_2 + b_{11}X_1^2 + b_{22}X_2^2 + b_{12}X_1X_2$

Formulation of factorial batches

Tablet compression

Optimized blend was compressed using rotary tablet machine.

Pre-compression evaluation

Blend tested for:

- Bulk Density
- Tapped Density
- Carr's Index
- Hausner Ratio
- Angle of Repose

Post-Compression Evaluation

Tablets tested for:

- Hardness
- Friability
- Weight Variation
- Drug Content
- Disintegration Time

Comparative dissolution study

Optimized formulation compared with marketed tablet.

Conditions:

- IP type I apparatus
- 100 rpm
- 37 ± 0.5°C

Drug release monitored.

Stability study

Optimized tablets wrapped and stored at: **40 ± 2°C / 75 ± 5% RH** for **1 month**. Evaluated periodically.

RESULTS AND DISCUSSION

Preformulation studies of Ebastine

Preformulation study was carried out to establish the physical and pharmaceutical characteristics of Ebastine prior to formulation development. The drug was observed as white crystalline powder. Melting point was found in the range of **82-86°C**, confirming identity and purity.

Flow properties were evaluated to understand handling characteristics during formulation. Angle of repose, density parameters and compressibility studies indicated acceptable flow. UV analysis confirmed λ_{max} in methanol and dissolution medium. The observations correlated with literature and confirmed suitability of the drug for further development.

Table 1: Characterization of pure Ebastine

Parameter	Observation
Appearance	White crystalline powder
Melting point	82-86°C
Angle of repose	35.04 ± 1.03
Bulk density (g/ml)	0.32 ± 0.03
Tapped density (g/ml)	0.38 ± 0.04
Carr's index (%)	15.37 ± 1.90
Hausner ratio	1.17 ± 0.03
λ_{max} in methanol	252 nm
λ_{max} in dissolution medium	256 nm

FTIR analysis of pure Ebastine

FTIR analysis was performed to confirm characteristic functional groups.

Characteristic peaks observed:

- C=O stretching - 1678.55 cm⁻¹
- C-N stretching - 1168.07 cm⁻¹
- C-O stretching - 1035.92 cm⁻¹
- C-H stretching - 1359.91 cm⁻¹

Observed peaks confirmed identity of Ebastine.




Figure 1: FTIR spectrum of pure Ebastine

Differential scanning calorimetry

DSC thermogram of Ebastine showed sharp endothermic peak at 86°C, confirming crystalline nature and purity.




Figure 2: DSC thermogram of pure Ebastine




Figure 3: PXRD of pure Ebastine

Powder X-ray diffraction

PXRD analysis showed sharp diffraction peaks indicating crystalline structure of pure drug.

Solubility study

Solubility of Ebastine was studied in selected non-volatile solvents. Cremophor RH 40 demonstrated highest solubility.

Table 2: Solubility study of Ebastine

Solvent	Solubility (mg/gm)
Cremophor RH 40	315.53 ± 1.65
Tween 20	181.14 ± 1.78
Tween 80	155.45 ± 1.02
PEG 600	125.86 ± 1.29
PEG 400	116.34 ± 1.46
Propylene glycol	67.49 ± 0.64

Cremophor RH 40 was selected as non-volatile solvent due to highest drug solubilization.




Figure 4: Solubility study graph

Selection of carrier and coating material

Neusilin US2 demonstrated excellent adsorption and carrier performance. Aerosil 200 showed efficient coating and dry powder formation. Both provided free-flowing powder suitable for compression.

Drug-excipient compatibility

FTIR spectra of drug and excipients showed characteristic peaks retained without major shift, No incompatibility observed.




Figure 5: Drug-excipient compatibility FTIR spectra

Preliminary trial batches

Preliminary batches were prepared for optimization of flow and dissolution.

Table 3: Preliminary trial batch evaluation

Batch	Angle of repose
A1	31.57 ± 0.13
A2	31.45 ± 0.40
A3	30.14 ± 0.17
A4	36.12 ± 0.26
A5	38.24 ± 0.18

A3 showed improved flow.

In vitro release of preliminary batches

Table 4: Drug release of preliminary batches

Batch	0 min	10 min	15 min	20 min	30 min	45 min
B1	0	38.67 ± 1.79	53.12 ± 1.09	78.77 ± 1.59	88.45 ± 1.55	93.58 ± 2.41
B2	0	49.61 ± 1.25	68.71 ± 1.54	84.01 ± 1.87	91.74 ± 2.36	94.32 ± 1.44
B3	0	47.65 ± 1.69	66.89 ± 1.26	86.18 ± 1.66	96.66 ± 1.97	98.84 ± 1.96
B4	0	50.44 ± 1.35	69.11 ± 1.92	83.22 ± 1.42	92.12 ± 1.67	96.06 ± 1.47
B5	0	51.52 ± 1.22	69.63 ± 1.68	82.54 ± 1.36	92.04 ± 2.01	95.19 ± 1.36

B3 showed maximum release.

Optimization by factorial design

Translation of coded values into actual units

Independent variables and variable levels

Independent variables	Low (-1)	Medium (0)	High (+1)
Drug concentration in liquid medication (%) (X_1)	15	20	25
Carrier coating ratio (R) (X_2)	20	25	30

Sr. No.	Dependent variables
1	Angle of repose ($^{\circ}$) (Y_1)
2	% cumulative drug release at 20 min (Y_2)

Table 5: Experimental design of factorial batches

Factorial	X ₁	X ₂	Actual X ₁ (%Cd)	Actual X ₂ (R)
F1	-1	-1	15	20
F2	0	-1	20	20
F3	+1	-1	25	20
F4	-1	0	15	25
F5	0	0	20	25
F6	+1	0	25	25
F7	-1	+1	15	30
F8	0	+1	20	30
F9	+1	+1	25	30

Table 6: Composition of factorial batches

Batch	Cd (%)	R	W (mg)	Lf	Carrier (Q)=W/Lf (Neusilin)	Coating (q)=Q/R (Aerosil 200)
F1	15	20	66.67	0.603	110.56	5.53
F2	20	20	50.00	0.603	82.91	4.14
F3	25	20	40.00	0.603	66.33	3.31
F4	15	25	66.67	0.574	116.14	4.64
F5	20	25	50.00	0.574	87.10	3.48
F6	25	25	40.00	0.574	69.68	2.78
F7	15	30	66.67	0.139	479.64	15.98
F8	20	30	50.00	0.139	359.71	11.99
F9	25	30	40.00	0.139	287.76	9.59

Optimization of Ebastine liquisolid compact was carried out using **3² full factorial design**. Drug concentration in liquid medication (X₁) and carrier coating ratio (X₂) was selected as independent variables because both parameters significantly influence powder flow and drug release.

Drug concentration in liquid medication was evaluated at three levels **15%, 20% and 25%**, while carrier coating ratio was studied at **20, 25 and 30**. Angle of repose (Y₁) and

percentage cumulative drug release at 20 minutes (Y₂) were selected as dependent variables. Nine experimental batches were prepared according to factorial design.

The design allowed evaluation of individual and combined influence of both formulation variables on flow properties and dissolution behavior and supported selection of optimized formulation using statistical software.

Table 7: Experimental results of factorial batches

Batch	X ₁ (% Cd)	X ₂ (R)	Y ₁ (Angle of repose, °)	Y ₂ (% cumulative drug release at 20 min)
F1	15	20	29.82 ± 0.69	76.83 ± 1.46
F2	20	20	28.91 ± 0.54	64.81 ± 1.56
F3	25	20	26.98 ± 0.87	58.86 ± 1.47
F4	15	25	30.12 ± 0.34	81.74 ± 2.04
F5	20	25	28.73 ± 0.77	67.78 ± 1.55
F6	25	25	26.89 ± 1.20	62.79 ± 1.16
F7	15	30	33.31 ± 0.93	85.61 ± 1.04
F8	20	30	31.86 ± 0.51	77.82 ± 1.36
F9	25	30	28.68 ± 0.58	71.85 ± 1.78

Table 8: Regression coefficients and p-values of responses

Variables	Y ₁ (Angle of repose) Coefficient	P value	Y ₂ (% cumulative drug release at 20 min) Coefficient	P value
Intercept	28.94	0.0017	68.90	0.0040
X ₁	-1.78	0.0005	-8.45	0.0010
X ₂	1.36	0.0012	5.80	0.0029
X ₁ X ₂	-0.45	0.0461	1.05	0.2748
X ₁ ²	-0.53	0.0694	2.81	0.0865
X ₂ ²	1.35	0.0060	1.86	0.1944

Table 9: Statistical summary of quadratic model

Quadratic model	R ²	Adjusted R ²	Predicted R ²	SD	%CV
Y ₁ (Angle of repose)	0.9937	0.9832	0.9362	0.27	0.92
Y ₂ (% cumulative drug release at 20 min)	0.9887	0.9700	0.8827	1.58	2.19

Statistical analysis of the quadratic model demonstrated excellent fitting for both dependent responses. For **angle of repose (Y₁)**, the model showed **R² value of 0.9937**, indicating that 99.37% of variability in the response was explained by formulation variables. The adjusted R² (**0.9832**) and predicted R² (**0.9362**) were in close agreement, confirming adequacy and predictive reliability of the model. For **percentage cumulative drug release at 20 minutes (Y₂)**, the model exhibited **R² value of 0.9887**, demonstrating strong correlation between observed and predicted values. The adjusted R² and predicted R² values also confirmed good model predictability. The low standard deviation values (**0.27 for Y₁ and 1.58 for Y₂**) indicated

minimal experimental error. Similarly, percentage coefficient of variation values (**0.92% and 2.19%**) were low, confirming reproducibility and precision of the experimental design. These findings established that the selected quadratic model was statistically valid and suitable for optimization of Ebastine liquisolid compact formulation.

Polynomial equations

For angle of repose: $Y_1 = +28.94 - 1.78X_1 + 1.36X_2 - 0.45X_1X_2 - 0.53X_1^2 + 1.35X_2^2$

For cumulative drug release: $Y_2 = +68.90 - 8.45X_1 + 5.80X_2 + 1.05X_1X_2 + 2.81X_1^2 + 1.86X_2^2$

Table 10: ANOVA for dependent variables

For Y₁ = Angle of repose

Source	Sum of squares	Degree of freedom	Mean square	F value	P value	Result
Regression	35.12	5	7.02	94.89	0.0017	Significant
Residual	0.22	3	0.074	—	—	—
Total	35.34	8	—	—	—	—

For Y₂ = % cumulative drug release at 20 min

Source	Sum of squares	Degree of freedom	Mean square	F value	P value	Result
Regression	656.83	5	131.37	52.66	0.0040	Significant
Residual	7.48	3	—	—	—	—
Total	664.31	8	—	—	—	—

Analysis of variance was performed to determine statistical significance of the selected quadratic model for both dependent variables. For **angle of repose (Y₁)**, the regression model showed an **F value of 94.89** with **p value 0.0017**, indicating that the model was statistically significant. The residual error was low, confirming good agreement between experimental and predicted values. For **percentage cumulative drug release at 20 minutes (Y₂)**, the regression model showed an **F value of 52.66** with **p value 0.0040**, indicating significant influence of formulation variables on

drug release. In both responses, p values were less than **0.05**, confirming statistical significance of the model.

ANOVA and response surface analysis

ANOVA showed significance of model. P value < 0.05. Response surface plots demonstrated:

- Increasing R Improved Drug Release
- Higher Cd Decreased Release
- Angle Of Repose Affected By Both Variables




Figure 6: Contour plot




Figure 7: Response surface plot

Validation of design and optimized formulation

After statistical analysis and response surface evaluation, optimized and checkpoint formulations were selected from the overlay plot region generated by Design Expert® software. These batches were prepared to validate the mathematical model and verify the predicted responses

experimentally. The optimized batch was obtained with **drug concentration in liquid medication (Cd) of 15.0** and **carrier-coating ratio (R) of 26.7**, while the checkpoint batch contained Cd 15.8 and R 27.2. Experimental observations were found to be in close agreement with predicted values, indicating accuracy of model fitting and reliability of optimization.

Table 11: Formula for optimized and checkpoint batch

Batch	Cd	R
Optimized batch	15.0	26.7
Checkpoint batch	15.8	27.2




Figure 8: Check Point Batch (CPB)




Figure 9: Optimized Batch (OPB)

Table 12: Validation of optimized and checkpoint batch

Parameter	Predicted	Observed
Angle of repose	30.97	30.32 ± 0.57
Drug release (%)	82.16	82.17 ± 0.87

The observed results were nearly identical to predicted values, confirming successful optimization.

Selection of superdisintegrant

Selection of suitable superdisintegrant was carried out to obtain rapid tablet disintegration and improve drug release. Three superdisintegrants were evaluated:

- Sodium Starch Glycolate
- Crospovidone
- Croscarmellose Sodium

Among these, crospovidone demonstrated faster disintegration.

Table 13: Selection of superdisintegrating agent

Superdisintegrant	Disintegration time (sec)
Sodium starch glycolate	180 ± 0.54
Crospovidone	162 ± 0.76
Croscarmellose sodium	165 ± 0.82

Crospovidone was selected.

Selection of crospovidone concentration

Further optimization of crospovidone concentration was carried out.

Table 14: Selection of crospovidone concentration

Concentration (%)	Disintegration time (sec)
5	163 ± 0.67
7	143 ± 0.74
9	141 ± 0.45

Although 9% showed marginally lower disintegration time, 7% was selected considering formulation performance and tablet characteristics.

Final optimized tablet composition

After optimization, final tablet formulation was prepared.

Table 15: Composition of optimized liquisolid compact tablet

Ingredient	Quantity (mg)
Ebastine	76.67
Neusilin US2	118.21
Aerosil 200	4.42
Crospovidone	14
Magnesium stearate	2
Total weight	215.30

The powder blend remained dry and free-flowing and was suitable for compression.

Evaluation of pre-compression parameters

Powder blend was evaluated before compression.

Table 16: Pre-compression parameters

Parameter	Result
Bulk density	0.28 ± 0.02
Tapped density	0.31 ± 0.03
Carr's index (%)	12.36 ± 1.89
Hausner ratio	1.14 ± 0.02
Angle of repose	30.85 ± 0.55

These values confirmed acceptable powder flow and compressibility.

Evaluation of post-compression parameters

Compressed tablets were evaluated for pharmacopeial quality.

Table 17: Post-compression parameters

Parameter	Result
Appearance	Uniform
Weight variation	Passed
Hardness	Acceptable
Friability	Within limit
Drug content	98.65 ± 0.66
Disintegration time	142 ± 0.17 sec

The tablets showed acceptable hardness and friability with satisfactory uniformity and drug content.

Comparative in vitro drug release study

The optimized liquisolid compact tablet was compared with marketed Ebastine tablet. The liquisolid compact showed significantly improved release profile. At 20 minutes:

- **Optimized tablet = 82.02 ± 1.47%**
- **Marketed tablet = 46.21 ± 1.04%**

Improved dissolution can be attributed to:

- Improved Wetting
- Enhanced Surface Area
- Better Drug Dispersion
- Reduced Crystallinity




Figure 10: Comparative in vitro drug release profile




Figure 11: FTIR spectra of optimized formulation

FTIR of optimized formulation

FTIR spectra of optimized formulation showed characteristic peaks retained without major shift.

This confirmed compatibility and absence of chemical interaction.

Differential scanning calorimetry of optimized formulation

DSC thermogram of optimized formulation showed reduction in intensity of drug melting peak.

This suggested conversion of crystalline drug into amorphous or molecularly dispersed form.




Figure 12: DSC thermogram of optimized formulation

Powder X-ray diffraction of optimized formulation

PXRD pattern of optimized formulation showed reduction in sharp crystalline peaks.

This supported decrease in crystallinity and improved dispersion.




Figure 13: PXRD pattern of optimized formulation

Stability studies

Accelerated stability study was performed at: $40 \pm 2^\circ\text{C} / 75 \pm 5\% \text{RH}$ for one month

Formulation remained stable.

Table 18: Stability study of optimized liquisolid compact

Parameter	Initial	After 1 month
Appearance	No chan	No change
Drug content	Accepta	Acceptable
Dissolution	Maintain	Maintained
Disintegration	Accepta	Acceptable

No significant change was observed.

CONCLUSION

The present findings indicate that liquisolid compact technology can serve as an effective platform for enhancing dissolution of poorly water-soluble antihistaminic drugs and may offer improved oral bioavailability and therapeutic efficacy."The present investigation successfully developed and optimized liquisolid compact tablets of Ebastine. Ebastine showed maximum solubility in Cremophor RH 40, which was selected as non-volatile solvent. Neusilin US2 and Aerosil 200 successfully converted liquid medication into dry compressible powder. Optimization using Design Expert® software and 3² factorial design generated reproducible formulation.

Crospovidone at 7% provided satisfactory disintegration.

The optimized tablets demonstrated for acceptable flow properties, acceptable compression, satisfactory tablet characteristics, enhanced dissolution compared with marketed tablet, compatibility between drug and excipients, reduced crystallinity & stability under accelerated conditions. The study confirmed that liquisolid compact technology is an effective and promising strategy for enhancement of dissolution of poorly water-soluble Ebastine and may contribute to improved oral bioavailability and therapeutic performance.

ACKNOWLEDGEMENT

The authors express sincere gratitude to the *Department of Pharmaceutics, Rofel Shri G. M. Bilakhia College of Pharmacy*, for providing the necessary laboratory facilities, academic support, and valuable guidance throughout the research work. The authors are also thankful to the suppliers for providing gift samples of Ebastine and the required excipients for carrying out the study successfully.

The authors further acknowledge the continuous encouragement and institutional support received from **Sharda School of Pharmacy**, Pethapur, Gandhinagar, Gujarat, India.

REFERENCES

- Vekariya D, Zalavadiya D. Enhancement of bioavailability of poorly water-soluble drugs by liquisolid technique: A review. *Int J Pharm Chem Sci.* 2012;1(2):850-858.
- Jung E, Kim JY, Ko D, Seo J, Lee SY, Lee D, Kim S, Park M, Kim S, Park S, Lee K. Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2-positive breast cancer. *International Journal of Molecular Medicine.* 2026 Apr 1;57(4):1-3.
- Sahoo CK, Das S, Mishra S, et al. Formulation and characterization of liquisolid tablets for improving dissolution of telmisartan. *FABAD J Pharm Sci.* 2025;50(1):5-18.
- Paun JS, Buddhadev S, Hirawala J, Christian P, Rathod N, Prajapati B. Optimization and Characterization of Lafutidine Liquisolid Pellets: A Novel Strategy for Improved Solubility and Drug Release. *BioNanoScience.* 2026 Feb 16;16(3):189.
- Vieira RJ, Gil-Mata S, Ferreira A, Riera-Serra P, Bognanni A, Duarte VH, Viegas H, Pereira AM, Ferreira-da-Silva R, Ferreira-Cardoso H, Marques-Cruz M. Efficacy and safety of oral antihistamines for allergic rhinitis: Network meta-analysis. *The Journal of Allergy and Clinical Immunology: In Practice.* 2026 Feb 16.
- Mehta S, Mansi P, Dudhat K, Borkhataria C, Soniwala M, Pethani T, Mehul R, Shah V, Manek R, Dhaval M. Liquisolid compact technology for enhancing the dissolution and bioavailability of Ticagrelor: DoE-based optimization and solid-state characterization. *Journal of Drug Delivery Science and Technology.* 2026 Mar 17:108241.
- Mohamed MS, Ogawa K, Mahmoud RA, Ramadan AE, Elkarim RA, El-Shenawy AA, Ozeki T. Formulation and Evaluation of Liquisolid Orally Disintegrating Tablets of Agomelatine with Natural Excipients for Enhanced Oral Bioavailability. *Journal of Pharmaceutical Innovation.* 2026 Aug;21(4):412.
- Paun JS, Buddhadev S, Hirawala J, Christian P, Rathod N, Prajapati B. Optimization and Characterization of Lafutidine Liquisolid Pellets: A Novel Strategy for Improved Solubility and Drug Release. *BioNanoScience.* 2026 Feb 16;16(3):189.
- Barot T, Patel J, et al. Liquisolid compact of meclizine hydrochloride: development and optimization using factorial design. *Int J Pharm Sci Res.* 2025;16(2):1-12.
- Rane B, Chaure P, Gawade S, Jain A, Shirode A, Kolhe Y. Design, Development, and Optimization of Ebastine-Loaded Nanofibers-Dispersed Transdermal Gel for the Chronic Urticaria (Hives). *Journal of Pharmaceutical Innovation.* 2026 Feb;21(1):48.
- Rane B, Chaure P, Gawade S, Jain A, Shirode A, Kolhe Y. Design, Development, and Optimization of Ebastine-Loaded Nanofibers-Dispersed Transdermal Gel for the Chronic Urticaria (Hives). *Journal of Pharmaceutical Innovation.* 2026 Feb;21(1):48.
- Mevada J, Patel K, Raval AM. Materiovigilance: From device failure to safety reform, the growing importance of materiovigilance systems. *Int J Pharm Sci.* 2026;4(1):962-74.
- Research Journal of Pharmacy and Technology. Refined liquisolid system for enhancement of dissolution profile of poorly water-soluble drugs. *Res J Pharm Technol.* 2025;18(7).
- Falwariya, R., Jethva, T., Raval, A.M. and Lokhande, D., 2026. Comprehensive review: Microneedle patches-A painless revolution in transdermal drug delivery. *World J Pharm Med Res.* 12(1), pp.199-207.
- Mevada J, Patel K, Raval AM. Role of pharmacovigilance in drug safety monitoring. *World J Pharm Med Res.* 2025;11(11):235-40.
- International Journal of Pharmaceutical Sciences Review and Research. Liquisolid technique: a newer approach for research in dissolution enhancement of poorly soluble drugs. *Int J Pharm Sci Rev Res.* 2025;85(8):1-9.
- World Journal of Biology Pharmacy and Health Sciences. Formulation and evaluation of liquisolid compact of nitrofurantoin for dissolution enhancement. *World J Biol Pharm Health Sci.* 2025;22(2):1-10.
- Hussain Y, Khan H, et al. The most recent advances in liquisolid technology. *Pharmaceutical Science Advances.* 2024; published online ahead of 2025 indexing.
- Biotech Asia. Liquisolid compact-based strategy for augmented solubility and dissolution profile of dolutegravir sodium. *Biotechnol Asia.* 2026;22(4)
- Kulkarni AS, Aloorkar NH. Liquisolid system: A review. *Int J Pharm Sci Nanotechnol.* 2010;3(1):795-802.
- Rathi S. Physicochemical Characterization and In-Vitro Dissolution Enhancement of Ranolazine Using Solid Dispersion Method. Available at SSRN 3507970. 2019 Dec 21.
- Hassan G, Jafar D, Jafar M. Improving dissolution of meloxicam using solid dispersion. *Indian J Pharm Res.* 2004;23:231-238.
- Yadav V, Yadav A. Enhancement of solubility and dissolution rate of BCS class II pharmaceuticals by nonaqueous granulation technique. *Int J Pharma Res Dev.* 2010;1(12):1-12.

24. Raval AM, Bhavsar PR, Pandya FU, Patel D. Co-processed excipients in pharmaceutical formulation: advances, characterization, and applications. *Asian Journal of Pharmaceutical Research and Development*. 2026 Feb 16;14(01):105-13.
25. Zaheer A, Maurya N. Solubility enhancement of poorly water-soluble drugs: A review. *Int J Pharm Tech*. 2011;3(1):807-823.
26. Patel N, Raval AM. Gastro-retentive drug delivery system: A review. *Int J Pharm Sci*. 2026;4(1):734-42.
27. Kadam SV. Review on solubility enhancement techniques. *Int J Pharm Bio Sci*. 2013;3(3):462-475.
28. Kumar S. Various techniques for solubility enhancement: An overview. *Pharma Innov J*. 2016;5(1):23-28.
29. Thakor AD, Dharajiya RM, Shaikh MZ, Raval AM. A review on neuropharmacology: mechanisms, drug classes, and clinical applications. *Asian Journal of Pharmaceutical Research and Development*. 2026 Feb 15;14(01):114-21.
30. Datkhile S, Jadhav S. Lquisolid compacts: A review. *Int J Inst Pharm Life Sci*. 2014;4(2):1-10.
31. Zankhwala MF, Raval MA, Kushkiwala MA, Sarvaiya MS, Raval MK, Thakar MN, Barjod MS. Formulation And Evaluation Of Optimized Polymer Blends For Diclofenac Diethylamine Transdermal System. *The Review of Diabetic Studies*. 2025 Sep 14:701-8.
32. Kumar C, Venugopalaiah P. Lquisolid systems: An emerging strategy for solubilization and dissolution rate enhancement of BCS class II drugs. *Int J Pharm Rev Res*. 2013;3(2):56-66.
33. Kumar PA, Mohmmmed N, Chandragirivar PC, Raval AM. Design space exploration of trazodone nanocrystals via DOE: formulation and in vitro-in vivo assessment. *Int J Drug Deliv Technol*. 2026;16(42s):1358-1368. doi:10.25258/ijddt.16.42s.146.
34. Chandragirivar PC, Banu A, Raval AM, Kusuma R, Srinidhi G, Yashwanth HB, Suheel A. Improved dissolution performance of fenopropfen calcium using PEG 6000 solid dispersions: preparation by fusion method and physicochemical characterization. *Int J Drug Deliv Technol*. 2026;16(36s):771-781. doi:10.25258/ijddt.16.36s.87.
35. Joshi SY, Detholia KK, Raval AM, Dharu NR, Rathod SR, Kushkiwala AM. Development and validation of a stability-indicating RP-HPLC method for quantitative estimation of sunitinib malate in pharmaceutical dosage form. *Int J Drug Deliv Technol*. 2026;16(12s):418-426. doi:10.25258/ijddt.16.12s.48.
36. Bhatt R, Raval AM, Patel J, Patel D. Oral thin film drug delivery systems for thrombosis therapy: a comprehensive review. *Int J Pharm Sci*. 2026;4(1):3563-3576. doi:10.5281/zenodo.18423515.
37. Prajapati A, Yadav P, Raval AM, Patel J. Review on solid dispersion-based fast dissolving tablets: formulation approaches and evaluation. *World J Pharm Med Res*. 2025;11(11):109-112. doi:10.5281/zenodo.17483241.
38. Rowe RC, Sheskey PJ, Quinn ME. *Handbook of Pharmaceutical Excipients*. 5th ed. London: RPS Publishing; p. 545.
39. Patel PS, Raval AM, Kumar PA, Kumar PP, Ghanshyam PT. A comprehensive review of antibiotic resistance: mechanisms, causes, and novel therapeutic approaches. *Asian Journal of Pharmaceutical Research and Development*. 2026 Apr 15;14(2):117-28.
40. Raval MA, Suthar MA, Durani MB, Thakar MN, Zankhwala MF, Kushkiwala MA, Rathod MS. Smart Co-Processed Excipient Platforms: A Novel Strategy for Multifunctional Optimization of Ibuprofen Tablet Formulations. *practice*.;1:2.
41. Kushkiwala AM, Zankhwala FM, Patel MD, Raval AM. Flurbiprofen loaded ethosomal gel: Design, optimization, and anti-inflammatory activity. *Int J Res Anal Rev*. 2024;11(4):709-42.
42. Shastri DH, Shaikh MT. A review on liquisolid system. *J Drug Deliv Ther*. 2014;4(3):25-31.
43. Amar M, Raval AMR, Krina N Chaudhari KNC, Dr. Bhoomi Arora DBA, Dr. Aastha Ukani DAU, Riddhi Modh RM, Dr. Kuldeep Choubisa DKC, Dr. Ashok Kumar DAK. Emerging Role of GLP-1 and Dual Incretin Agonists in the Management of Type 2 Diabetes Mellitus: Mechanisms, Clinical Evidence, Dosing Strategies, and Future Perspectives. *International Journal of Medical and Pharmaceutical Research*. 2026 May;7(3):357-370.
44. Chandel P, Kumari R, Kapoor A. Liquisolid technique: An approach for enhancement of solubility. *J Drug Deliv Ther*. 2013;3(4):131-137.
45. Upadhyay J, Yadav P, Patel D, Raval A, Patel J. Review on in-situ depot-based controlled drug delivery for treatment of rheumatoid arthritis treatment. *World Journal of Pharmaceutical and Medical Research*. 2025 Nov;11(11):113-117. doi:10.5281/zenodo.17483326
46. Sayed IA, Pavani E. The liquisolid technique-based drug delivery system. *Int J Pharm Sci Drug Res*. 2012;4(2):88-96.
47. Raval AM, Rana T, Joshi SY, Buch S, Arora B, Patel VS. Artificial intelligence in pharmacy and healthcare: applications in drug discovery, precision medicine, clinical practice, and future perspectives. *Asian Journal of Pharmaceutical Research and Development*. 2026 Apr 15;14(2):62-9.
48. Peddi MG. Novel drug delivery system: Liquisolid compact. *J Mol Pharm Org Process Res*. 2013;1(3):1-5.
49. kumar Patel PB, Raval AM, Patel HB, Patel KH, Poorv P, Vaidya PA, Kahar KH. A comprehensive review of polycystic ovary syndrome (PCOS): pathophysiology, diagnosis and management. *Asian Journal of Pharmaceutical Research and Development*. 2026 Apr 15;14(2):32-41.
50. Senjaliya T, Patel M, Raval AM. Strategies for combating the global health threat of antibiotic resistance: novel therapeutics and combination approaches. *Asian Journal of Pharmaceutical Research and Development*. 2026 Feb 15;14(01):122-30.
51. Chaplin DD. Overview of the human immune response. *J Allergy Clin Immunol*. 2006;117:S430-S435.
52. Raval AM, Maneklal RJ, Dilipbhai MU. Development and Evaluation of Polyherbal Topical Cream for Wound Healing Applications Using Alum, Turmeric, and Aloe Vera. *Asian Journal of Pharmaceutical Research and Development*. 2026 Apr 15;14(2):234-40.
53. Brodie DH. The pathophysiology of allergic rhinoconjunctivitis. *Allergy Asthma Proc*. 2007;28:398-403.
54. Choi SH. Bronchial hyperresponsiveness in young children with allergic rhinitis and associated risk factors. *Allergy*. 2007;62:1051-1056.
55. Raval AM, Utpalkumar PF, Utpalkumar PV, Ratnakar BP. Development and Evaluation of Multifunctional Co-Processed Excipients for Fast Dissolving Tablet Formulation. *Asian Journal of Pharmaceutical Research and Development*. 2026 Apr 15;14(2):226-33.
56. Bousquet J, Warner JO. Requirements for medications commonly used in treatment of allergic rhinitis. *Allergy*. 2003;58:192-197.
57. Simons FE. Advances in H1-antihistamines. *N Engl J Med*. 2004;351:2203-2217.
58. Raval AM, Verma AR, Prajapati DS. Efficacy and Safety of Major Antihypertensive Drug Classes in Adults with Hypertension: A Systematic Review. *Asian Journal of Pharmaceutical Research and Development*. 2026 Apr 15;14(2):216-25.
59. Wahn U. Levocetirizine in children: Efficacy and safety in a randomized seasonal allergic rhinitis trial. *Pediatr Allergy Immunol*. 2005;16:267-275.
60. McNeely W, Wiseman LR. Intranasal azelastine: A review of efficacy in allergic rhinitis. *Drugs*. 1998;56:91-114.
61. Panthaki J, Bhai YL, Kumar VS, Raval AM. Formulation and Evaluation of Body Scrub Using Walnut Shell Powder. *Asian Journal of Pharmaceutical Research and Development*. 2026 Apr 15;14(2):241-7.
62. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists in allergic rhinitis: Systematic review and meta-analysis. *Ann Allergy Asthma Immunol*. 2002;89:479-484.
63. Berger WE, White MV. Efficacy of azelastine nasal spray in patients with unsatisfactory response to loratadine. *Ann Allergy Asthma Immunol*. 2003;91:205-211.
64. Lee BJ, Kim YJ. Comparative study of intranasal budesonide and oral terfenadine in perennial allergic rhinitis. *J Asthma Allergy Clin Immunol*. 2001;21:216-222.
65. Dhamne MR. TABLET DOSAGE FORM. *Journal of Pharmaceutical Research*. 2015 Jul;14(3):66-70.